Same-day preeclampsia test rolled out in UK
A same-day blood test that can rule out preeclampsia in pregnant women is being rolled out across the National Health Service (NHS) in England.
The NHS is a publicly funded health care system and 1 of 4 in the United Kingdom.
Preeclampsia is dangerous for both mother and baby and can often lead to preterm birth and even increase the risk of stroke later in life in women with a history of preeclampsia.
The test—placental growth factor (PLGF) testing—is the first of its kind to exclude the life-threatening condition and is being used in 75% of the maternity wards in England. According to an article from Independent, 65,000 expectant mothers are admitted to the hospital for up to 3 days to be monitored each year. The blood test can be used, according to research, to indicate who needs admission and intensive monitoring, and who can be discharged.
Normal test results mean that preeclampsia is not developing over the next 1-2 weeks, and the mother can safely resume her routine antenatal surveillance.
This test, and further research on its effectiveness, may shed light on ways U.S. health care systems can better aid women with high blood pressure and/or preeclampsia.
Adverse pregnancy outcomes linked to midlife cardiovascular disease risk
September 11th 2024In a recent study presented at the 2024 Annual Meeting of The Menopause Society, women with certain adverse outcomes during pregnancy had an increased risk of cardiovascular disease later in life.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Nipocalimab shows promise in preventing hemolytic disease of the fetus and newborn
August 21st 2024The investigational drug could prevent the rare fetal disease HDFN (hemolytic disease of the fetus and newborn) by stopping harmful antibodies from transferring through the placenta during pregnancy.
Read More
